IPO Issue Details
Issue Price / Price Band₹426 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size35 Shares per Lot
Total Issue Size3,11,16,785 shares (aggregating up to ₹1,330.51 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenTue, 06 Dec 2016
Subscription CloseThu, 08 Dec 2016
Anchor AllotmentMon, 05 Dec 2016
Basis of AllotmentWed, 14 Dec 2016
Initiation of RefundsThu, 15 Dec 2016
Credit of Shares to DematFri, 16 Dec 2016
Listing DateMon, 19 Dec 2016
UPI Mandate Deadline2016-12-08
Application & Investment Details
Retail — Min (1 Lots)₹14,980 — 35 shares
Retail — Max (13 Lots)₹193,830 (13 Lots)
HNI — Min (14 Lots)₹2,09,720 — 490 shares
Pre-IPO Promoter Holding9,87,46,904 shares
Post-IPO Promoter Holding10,57,56,249 shares
About Laurus Labs Ltd
About Laurus Labs Ltd.Incorporated in 2005, Laurus Labs Ltd is Hyderabad based pharmaceutical company. Laurus Labs is in the business of manufacturing generic active pharmaceutical ingredients (APIs) for therapeutic areas of antiretrovirals (ARVs) and Hepatitis C. Company also manufacture APIs in oncology and other therapeutic areas.Laurus Labs operates in four business lines:1. Generics active pharmaceutical ingredients (APIs) - The development, manufacture and sale of APIs and advanced intermediates.2. Generics finished dosage forms (FDFs) - The development and manufacture of oral solid formulations.3. Synthesis - Contract development and manufacturing services for global pharmaceutical companies.4. Ingredients - The manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors.Key Highlights:1. Laurus Labs launched 59 products since our inception in 2005.2. Nine out of the 10 largest generic pharmaceutical companies in the world are its customers.3. Laurus Labs employed 587 scientists at our R&D center in Hyderabad and 12 scientists at R&D centre in Greater Boston USA.4. The Company owned 32 patents and had 150 pending patent applications, in several countries.5. Company has three manufacturing facilities in Visakhapatnam, Andhra Pradesh.6. Company sells its products in 32 countries in Sub-Saharan Africa, South-East Asia and Latin America.Key Strengths:1. Leadership in APIs in Select, High Growth Therapeutic Areas2. Strong R&D Capabilities and Process Chemistry Skills3. Industry Leading, Modern and Regulatory Compliant Manufacturing Capacities4. Long-standing Relationships with Multi-National Pharmaceutical Companies5. Experienced Promoters and Qualified Operational Personnel6. Established Track Record of Delivering Growth
Objects of the Issue
Laurus Labs Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Pre-payment of term loans
226.29
2
General corporate purposes
60.42
Shareholding & Lock-in
Pre-IPO Promoter Holding
9,87,46,904 shares
Post-IPO Promoter Holding
10,57,56,249 shares